SWK Holdings Corporation, a specialty finance company, focuses on the healthcare sector. The company operates in two segments, Finance Receivables and Pharmaceutical Development. It provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. The company, through its subsidiary, SWK Advisors LLC, offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. The company also engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Its product pipeline includes Ovarest, an oral leuprolide tablet to treat endometriosis; and Tobrate, an oral tobramycin tablet for the treatment of uncomplicated urinary tract infections. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was incorporated in 1996 and is headquartered in Dallas, Texas.
IPO Year:
Exchange: NASDAQ
Website: swkhold.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/28/2022 | $26.00 | Buy | Lake Street |
| 4/18/2022 | $26.00 | Buy | Lake Street |
4 - SWK Holdings Corp (0001089907) (Issuer)
4 - SWK Holdings Corp (0001089907) (Issuer)
4 - SWK Holdings Corp (0001089907) (Issuer)
3 - SWK Holdings Corp (0001089907) (Issuer)
3 - SWK Holdings Corp (0001089907) (Issuer)
3 - SWK Holdings Corp (0001089907) (Issuer)
3 - SWK Holdings Corp (0001089907) (Issuer)
3 - SWK Holdings Corp (0001089907) (Issuer)
3 - SWK Holdings Corp (0001089907) (Issuer)
4 - SWK Holdings Corp (0001089907) (Issuer)
SC 13G/A - SWK Holdings Corp (0001089907) (Subject)
SC 13D/A - SWK Holdings Corp (0001089907) (Subject)
SC 13G/A - SWK Holdings Corp (0001089907) (Subject)
SC 13G/A - SWK Holdings Corp (0001089907) (Subject)
SC 13G/A - SWK Holdings Corp (0001089907) (Subject)
SC 13G/A - SWK Holdings Corp (0001089907) (Subject)
SC 13G - SWK Holdings Corp (0001089907) (Subject)
SC 13D/A - SWK Holdings Corp (0001089907) (Subject)
SC 13D/A - SWK Holdings Corp (0001089907) (Subject)
SC 13D/A - SWK Holdings Corp (0001089907) (Subject)
New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema. CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. Funds raised will provide ImpediMed with funding flexibility and will be used to support growth and commercialization activities. Armentum Partners acted as the Company's exclusiv
January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists
DALLAS, TX / ACCESSWIRE / January 6, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update for material events occurring since September 30, 2024.OriginationsIn November, SWK advanced $5.0M to existing borrower Journey Medical to help fund the company's launch of EmrosiTM.In November, as part of a broader amendment SWK advanced $0.6M to existing borrower Biotricity. On amendment closing, SWK received 600,000 warrants to purchase Biotricity stock at $0.50 per share.In December, SWK closed an $8.0M senior secured term loan with Triple
Conference Call Scheduled for Friday, November 15, 2024, at 09:00 a.m. CSTCorporate HighlightsThird quarter 2024 GAAP net income was $3.5 million, compared with GAAP net income of $4.5 million for the third quarter 2023.Third quarter 2024 finance receivables segment adjusted non-GAAP net income was $5.0 million, compared with adjusted non-GAAP net income of $5.8 million for the third quarter 2023.As of September 30, 2024, net finance receivables were $255.9 million, a 14.4% increase from September 30, 2023.The third quarter 2024 effective yield was 14.6%, a 60 basis points increase from third quarter 2023.As of September 30, 2024, GAAP book value per share was $22.94, a 3.7% increase from $2
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results
Conference Call Scheduled for Friday, August 16, 2024, at 09:00 a.m. CSTCorporate HighlightsSecond quarter 2024 GAAP net income was $4.4 million, compared with net income of $3.9 million for the second quarter 2023Second quarter 2024 finance receivables segment adjusted non-GAAP net income was $6.5 million, compared with adjusted non-GAAP net income of $7.6 million for the second quarter 2023As of June 30, 2024, net finance receivables were $265.5 million, a 19.0% increase from June 30, 2023The second quarter 2024 effective yield was 14.6%, a 10 bps increase from second quarter 2023As of June 30, 2024, non-GAAP tangible financing book value per share was $20.17, a 6.3% increase from $18.95 a
DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st
Company Also Promotes Controller DALLAS, TX / ACCESSWIRE / July 8, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, is pleased to announce the appointment of Adam C. Rice, CPA, as Chief Financial Officer (CFO) of the company and the promotion of Courtney Baker, CPA, to Controller.With over 18 years of senior-level finance and accounting leadership experience, Rice has led financial operations management, corporate financial planning and analysis, strategic planning and financial statement reporting. He was previously CFO of Park Cities Asset Management, an SEC
Conference Call and Live Audio Webcast Scheduled for Thursday, May 16, 2024, at 10:00 a.m. ET Corporate HighlightsFirst quarter 2024 GAAP net income was $0.9 million, compared with net income of $4.6 million or $0.36 per share, for the first quarter 2023First quarter 2024 finance receivables segment adjusted non-GAAP net income was $2.7 million, compared with adjusted non-GAAP net income of $7.3 million for the first quarter 2023As of March 31, 2024, gross finance receivables were $274.5 million, a 10.3% increase from March 31, 2023As of March 31, 2024, book value per share was $22.46As of March 31, 2024, non-GAAP tangible financing book value per share was $19.69First quarter 2024 finance p
Conference Call and Live Audio Webcast Scheduled for Thursday, March 21, 2024, at 10:00 a.m. ETCorporate HighlightsFourth quarter 2023 and 2022 net income was $2.8 millionFull year 2023 net income was $15.9 million, compared to full year 2022 net income of $13.5 millionClosed a $33.0 million public offering of senior notesRepurchased 14,233 shares of common stock during the fourth quarter for a total cost of $0.2 million; year-to-date 2024 through March 14th, repurchased an additional 51,169 shares for a total cost of $0.9 millionAfter quarter end, signed Exclusive Option and Asset Purchase Agreement granting strategic partner an exclusive two-year option to purchase certain tangible assets
Lake Street resumed coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00
Lake Street initiated coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00
January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists
Company Also Promotes Controller DALLAS, TX / ACCESSWIRE / July 8, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, is pleased to announce the appointment of Adam C. Rice, CPA, as Chief Financial Officer (CFO) of the company and the promotion of Courtney Baker, CPA, to Controller.With over 18 years of senior-level finance and accounting leadership experience, Rice has led financial operations management, corporate financial planning and analysis, strategic planning and financial statement reporting. He was previously CFO of Park Cities Asset Management, an SEC
NEW BRITAIN, Conn., May 2, 2023 /PRNewswire/ -- Stanley Black & Decker (NYSE:SWK) today announced the appointment of Chris Nelson as Chief Operating Officer of the company, and Executive Vice President and President of Tools & Outdoor, effective June 14, 2023. Nelson joins Stanley Black & Decker from Carrier Corporation and brings more than 25 years of leadership experience in general management, product development and innovation, and growth transformation. Nelson will report to Donald Allan Jr., President and CEO of Stanley Black & Decker. He will assume the role of President, Tools & Outdoor, from current Acting Co-Presidents Robert Raff and John Wyatt. Raff will continue to serve as Chie
DALLAS, March 15, 2023 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that Jerry Albright has been named to the Company's Board of Directors and will replace Wendy DiCicco, who chose not to seek re-election to the Board because of external professional commitments. The transition will be effective March 15, 2023, with Mr. Albright joining Board Chair, Laurie Dotter, and directors, Robert K. Hatcher, and Marcus Pennington, on the Board. "We are pleased to welcome Jerry to SWK's Board of Directors and look forward to benefitting from
Mr. Staggs elevated from "interim" to "permanent" CEO as SWK advances multiple initiatives in 2023 Ms. Dotter joined SWK's Board of Directors in February 2022 DALLAS, Jan. 3, 2023 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that Jody Staggs has been named the company's Chief Executive Officer. In September 2022, Mr. Staggs was promoted to the position of President and interim Chief Executive Officer. Effective January 1, 2023, Mr. Staggs holds the titles of President and Chief Executive Officer of SWK Holdings. Additionally, SWK
Jody Staggs appointed as President and Interim CEO CEO Winston Black will assist in an interim consulting role after successfully establishing SWK Holdings as a leading life science focused specialty finance company Portfolio and pipeline remain strong as evidenced by recent closing of two $25 million credit agreements DALLAS, Sept. 1, 2022 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that Jody Staggs, Managing Director of SWK Holdings, has been promoted to the position of President, effective September 1, 2022, and will serve as in
BOONTON, N.J., Jan. 7, 2021 /PRNewswire/ -- Rajiv Khosla, Ph.D., named Chief Executive Officer Gary A. Shangold, M.D., appointed Chief Medical Officer Received two milestone payments totaling $5 million from Cara Therapeutics per licensing agreement for Peptelligence to advance development of Oral KORSUVA™ Additional potential milestone payments expected over the next several quarters, subject to the achievement of certain development milestones for Oral KORSUVA Oral KORSUVA currently the subject of three separate, ongoing clinical programs focused on distinct pruritis indications Expansion of manufacturing facility to enable Phase 3 and small volume commercial scale production, in
Conference Call Scheduled for Friday, November 15, 2024, at 09:00 a.m. CSTCorporate HighlightsThird quarter 2024 GAAP net income was $3.5 million, compared with GAAP net income of $4.5 million for the third quarter 2023.Third quarter 2024 finance receivables segment adjusted non-GAAP net income was $5.0 million, compared with adjusted non-GAAP net income of $5.8 million for the third quarter 2023.As of September 30, 2024, net finance receivables were $255.9 million, a 14.4% increase from September 30, 2023.The third quarter 2024 effective yield was 14.6%, a 60 basis points increase from third quarter 2023.As of September 30, 2024, GAAP book value per share was $22.94, a 3.7% increase from $2
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results
DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st
Conference Call and Live Audio Webcast Scheduled for Thursday, May 16, 2024, at 10:00 a.m. ET Corporate HighlightsFirst quarter 2024 GAAP net income was $0.9 million, compared with net income of $4.6 million or $0.36 per share, for the first quarter 2023First quarter 2024 finance receivables segment adjusted non-GAAP net income was $2.7 million, compared with adjusted non-GAAP net income of $7.3 million for the first quarter 2023As of March 31, 2024, gross finance receivables were $274.5 million, a 10.3% increase from March 31, 2023As of March 31, 2024, book value per share was $22.46As of March 31, 2024, non-GAAP tangible financing book value per share was $19.69First quarter 2024 finance p
DALLAS, TX / ACCESSWIRE / January 23, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower partners."We concluded 2023 with a surge in deal activity as the 2023 investments SWK has made in the team and underwriting process paid dividends through an increased pipeline and four deal closings," stated Jody Staggs, President and CEO of SWK. "During the quarter, SWK closed approximately $60 million of financings with $55 million deployed. With these new capital deployments
Conference Call and Live Audio Webcast Scheduled for Wednesday, August 9, 2023, at 5:00 p.m. ET Corporate Highlights Second quarter 2023 GAAP net income was $3.9 million or $0.31 per diluted share, compared with net income of $0.6 million or $0.04 per diluted share, for the second quarter 2022Closed a $45.0 million credit facility with First Horizon BankYear-to-date Enteris has booked $2.0 million of CDMO projects and has $9.0 million of CDMO proposals outstanding, which is expected to drive revenue growth in 2H23During the quarter SWK repurchased 272,492 shares of common stock for a total cost of $4.6 million, or $16.88 per share; Year-to-date through August 5, 2023, SWK has repurchased 327
Conference Call and Live Audio Webcast Scheduled for Wednesday, August 9, 2023, at 5:00 p.m. ET DALLAS, Aug. 8, 2023 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, announced today that the Company will host a conference call and live audio webcast on Wednesday, August 9, 2023, at 5:00 p.m. ET, to discuss its corporate and financial results for the second quarter of 2023. Interested participants and investors may access the conference c
Board Of Directors Approves Quarterly Cash Dividend Increase To $0.81 Per Share NEW BRITAIN, Conn., July 27, 2023 /PRNewswire/ -- Stanley Black & Decker (NYSE:SWK), a worldwide leader in tools and outdoor, announced today that its Board of Directors approved a $0.01 increase of its quarterly cash dividend to $0.81 per common share. The dividend is payable on Tuesday, September 19, 2023, to shareholders of record as of the close of business on Tuesday, September 5, 2023. Stanley Black & Decker's President and CEO, Donald Allan, Jr., commented, "We are pleased to announce this dividend increase as our long-standing commitment to rewarding shareholders through growing cash dividends is a key el
Conference Call and Live Audio Webcast Scheduled for Thursday, May 11, 2023, at 10:00 a.m. ET Corporate Highlights First quarter 2023 GAAP net income was $4.6 million or $0.36 per diluted share, compared with net income of $3.5 million or $0.27 per share, for the first quarter 2022Enteris has bid on approximately $7.0 million of CDMO projects year-to-date which is expected to drive revenue growth in 2H23Enteris first quarter 2023 operation expenses declined 45% compared with the fourth quarter 2022Michael Miner joined SWK as Vice President of Investments and Peter Blumberg joined as Vice President of Business DevelopmentSWK repurchased 28,766 shares of common stock during the quarter for a t
Conference Call and Live Audio Webcast Scheduled for Today, April 3, 2023, at 10:00 a.m. ET Corporate Highlights Jody Staggs named President and Chief Executive OfficerAppointed Laurie Dotter as Chair of the Board and Jerry Albright to the Board of DirectorsRestructuring at Enteris with quarterly operating expenses expected to decline by over $1.0 million per quarter by third quarter 2023Repurchased 29,438 shares of common stock during the quarter for a total cost of $0.5 million and YTD 2023 have purchased an additional 27,291 shares of common stock for a total cost of $0.5 millionFinance Receivables Segment Update Fourth quarter 2022 GAAP net income was $2.8 million, compared with net inco
8-K - SWK Holdings Corp (0001089907) (Filer)
8-K - SWK Holdings Corp (0001089907) (Filer)
8-K - SWK Holdings Corp (0001089907) (Filer)
10-Q - SWK Holdings Corp (0001089907) (Filer)
DEFR14A - SWK Holdings Corp (0001089907) (Filer)
ANNLRPT - SWK Holdings Corp (0001089907) (Filer)
DEF 14A - SWK Holdings Corp (0001089907) (Filer)
DEFA14A - SWK Holdings Corp (0001089907) (Filer)
8-K - SWK Holdings Corp (0001089907) (Filer)
8-K - SWK Holdings Corp (0001089907) (Filer)